Mayflower Financial Advisors’s AstraZeneca AZN Stock Holding History

Mayflower Financial Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$240K	Buy	1,282 +60	+5%	+$11.3K	0.02%	427
2026 Q1	$237K	Buy	1,222 +100	+9%	+$19.3K	0.03%	402
2025 Q4	$206K	Buy	+1,122	New	+$197K	0.02%	399
2025 Q2	–	Sell	-1,391	Closed	-$204K	–	392
2025 Q1	$204K	Buy	+1,391	New	+$201K	0.03%	377
2024 Q4	–	Sell	-1,471	Closed	-$229K	–	383
2024 Q3	$229K	Buy	1,471 +25	+2%	+$4.04K	0.03%	337
2024 Q2	$226K	Buy	+1,446	New	+$218K	0.04%	323

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Mayflower Financial Advisors's AZN Position: Q2 2026 in Review

Mayflower Financial Advisors increased its AstraZeneca (AZN) stake by 4.9% in Q2 2026, buying an estimated $11.3K and bringing the position to 1,282 shares worth $240K. The position accounts for 0.02% of the portfolio, ranked #427.

Mayflower Financial Advisors first reported a position in AZN in Q2 2024 and has held it in 6 quarters since. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Mayflower Financial Advisors held 1,282 shares of AstraZeneca worth $240K as of Q2 2026.
Mayflower Financial Advisors bought 60 AstraZeneca shares in Q2 2026, an estimated $11.3K.
AstraZeneca made up 0.02% of Mayflower Financial Advisors's portfolio in Q2 2026, its #427 holding.
Mayflower Financial Advisors first reported a position in AstraZeneca in Q2 2024 and has held it in 6 quarters since.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Mayflower Financial Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.